{"entity":{"id":"nct06877650","kind":"trial","name":"First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors","aka":[],"tldr":"A phase 1/2 trial of Pembrolizumab and Ivonescimab in advanced solid tumours, run by Shanghai JMT-Bio Inc., now recruiting.","summary":"First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT06877650 by Shanghai JMT-Bio Inc., with 436 participants planned, started 2025-04-11 and due to reach its primary completion in 2028-03-30. Interventions recorded: JMT108, Pembrolizumab and Ivonescimab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06877650","url":"https://clinicaltrials.gov/study/NCT06877650"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","ivonescimab"],"companies":["cspc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06877650","phase":"1/2","setting":"A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JMT108 Injection in Participants With Advanced Malignant Tumors.","sponsor":"Shanghai JMT-Bio Inc.","enrolled":436,"outcomes":[]},"route":"/trials/nct06877650/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}]}}